Baird Downgrades Ultragenyx Pharma (RARE) to Neutral

September 3, 2026 4:09 AM

Baird analyst Joel Beatty downgraded Ultragenyx Pharma (NASDAQ: RARE) from Outperform to Neutral with a price target of $16.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found